very year authoritative bodies churn out their ''Top 10'' lists of quantifiable milestones they decide require enumerating in such a fashion. Invariably, one or more milestones are inadvertently (or perhaps not) left off the list, angering some, elating others. As we approach year's end, it seems fitting that we too take some time to reflect on 10 of 2008's most significant milestones. In the process, I offer a caveat . . . while every attempt has been made to be comprehensive, no such top 10 list ever can be, thus my apologies in advance for any glaring omissions.
Drum Roll, Please . . . No 1. Amid feverish global efforts to universalize access to antiretroviral therapy (ART), the Joint United Nations Programme on HIV/AIDS (UNAIDS) announced in July 2008 that the number of people who died from AIDS-related complications has declined worldwide for the second consecutive year. According to UNAIDS, Global AIDS-related deaths numbered about 2 million in 2007, down from 2.1 million in 2006. In 2005, AIDS-related deaths peaked at 2.2 million. Delivering a bit of good news, UNAIDS also announced a decline in new HIV infections from 3 million in 2001 to 2.7 million in 2007. But, although the number of new HIV infections has fallen in several countries, they are rising in many other countries such as China, Indonesia, Kenya, Mozambique, Papua New Guinea, the Russian Federation, the Ukraine, and Vietnam. Increases are also being seen in some older epidemics, and HIV incidence is on the rise in countries such as Australia, Germany, and the United Kingdom. 1 No 2. When compared to the highly individualized approach to ART delivery in the developed world, programmatic ART delivery in resource-limited settings results in similar virologic outcomes, with relatively few changes to initial antiretroviral regimens. Evidence to that effect was presented at the XVII International AIDS Conference in Mexico City, including results from a study in Botswana, which established a national treatment program and began providing its citizens free ART in January 2002. The overall 6-year survival rate of patients enrolled in the ART program was 86%. As of December 2007, a total of 92 932 patients were on ART in Botswana. 2 There remains a gap, however, around data related to optimizing ART delivery in resource-limited settings, with a few but very notable contributions published in 2008:
One study found that delays in initiating ART contribute to high mortality rates, thus requiring faster expansion and timely commencement of ART. 3 Another study reported that virological outcomes were inferior when nevirapine (NVP)-based ART was commenced while taking antitubercular treatment versus without concurrent tuberculosis (TB) but comparable when starting efavirenz (EFV)-based ART versus without concurrent TB or when TB developed while taking established NVP-or EFV-based ART. 4 And, yet another study demonstrated that pharmacy refill adherence assessments are as accurate a predictor of virologic failure in patients on ART as CD4 counts and may thus be used to identify those who are at high and low risk of virologic failure, potentially before it occurs. 5 in 2003, and its US$15 billion investment has been widely credited with, among other accomplishments, providing ART for more than 1.7 million people worldwide, the vast majority of them in sub-Saharan Africa. The new legislation will dramatically increase the financial commitment to this fight-authorizing up to US$48 billion to combat global HIV/AIDS, TB, and malaria. 6 No 4. Discouraging epidemiological data of ongoing HIV transmission among men who have sex with men (MSM) in the United States and around the world were presented at the XVII International AIDS Conference in Mexico City, 1 as was an American Foundation for AIDS Research (amfAR) report indicating that while HIV disease has come to increasingly affect women and children, MSM-the demographic originally considered most at risk-remains at highest risk of HIV infection. According to the report, research has found that MSM are 19 times more likely to be living with HIV/AIDS than the general population, yet they are ignored in many countries. Based on data submitted to UNAIDS from 128 countries, the report also found that 44% of countries failed to provide any data on MSM, thus implying a lack of disease surveillance. 7 No 5. Several studies shed worrisome light on the impact that specific antiretroviral drugs and/or ART has on non-HIV morbidity and mortality. For example, 2 studies-1 presented at the XVII International AIDS Conference in Mexico City, and the other at the 15th Conference on Retroviruses and Opportunistic Infections (CROI)-confirmed an unforeseen association between current use of the nucleoside reverse transcriptase inhibitor (NRTI) abacavir (ABC) and cardiovascular disease (CVD) risk. 8, 9 Still more troubling, however, is the growing body of evidence that ART is contributing to increased CVD, liver disease, renal disease, and non-HIV cancers among treatment-experienced HIV-positive patients. 10 No 6. Results of the multicountry AIDS Treatment for Life International Survey (ATLIS)-which were presented at the XVII International AIDS Conference in Mexico City and subsequently published in the July/August 2008 issue of JIAPAC 11 -indicate people living with HIV/AIDS around the globe still live in fear of the societal stigma that surrounds HIV disease. More than half of survey respondents (54%) are ''very'' or ''somewhat'' concerned about others knowing their HIV status. With respect to side effects, study results show that 26% of survey respondents reported they had elected not to initiate treatment because they believe that ART causes too many side effects. In addition, the survey results demonstrated critical gaps in HIV literacy. For example, when respondents were asked to describe how HIV drug resistance develops, only 17% accurately answered the question; previous studies have demonstrated a strong correlation between a good understanding of HIV drug resistance and improved treatment adherence. 12 No 7. After two decades of a largely biomedical approach to addressing the global HIV pandemic, there were developments around nontraditional approaches to health care delivery, including task shifting to expand available human resources and facilitate universal access to HIV prevention, care, and treatment services. 13 Also newsworthy were positive results from pilot programs testing the beneficial impact of microcredit in resource-limited settings as both a poverty intervention and as assistance to households and communities to provide education, care, treatment, and support to women, orphans, and vulnerable children. 14, 15 No 8. The US Food and Drug Administration (FDA)-with the European Medicines Agency (EMEA) and other drug regulatory bodies subsequently following suit-approved several new antiretroviral drugs in late 2007 and early 2008 specifically for treatment-experienced patients. These included 2 drugs from 2 new classes-the integrase inhibitor raltegravir 16 and the entry inhibitor maraviroc 17as well as etravirine, a second generation nonnucleoside reverse transcriptase inhibitor (NNRTI). 18 Four new drugs are in phase III trials-apricitabine (NRTI), elvitegravir (integrase inhibitor), rilpivirine (NNRTI), and vicriviroc (entry inhibitor).
No 9.
Late last year, Merck & Co and the US National Institute of Allergy and Infectious Diseases (NIAID) announced that they were halting development of an adenovirus-based HIV vaccine candidate because data from the STEP study showed V520 neither lowered the risk of HIV infection nor delayed disease progression. 19 Another disappointment followed 8 months later when the NIAID's Vaccine Research Center cancelled its PAVE 100 study, which was to have enrolled 8500 volunteers in the United States, South America, the Caribbean, and Eastern and Southern Africa. 20 The news was not much rosier on the microbicide front. Population Council researchers announced a study of their microbicide candidate Carraguard, the first ever to complete phase III testing, found it to have no significant effect on HIV transmission. 21 Also that month researchers decided to stop one arm of the Microbicides Development Programme 301 (MDP301) phase III trialwhich was testing a higher dose of the microbicide candidate PRO 2000-because it was unlikely to be beneficial; a weaker version would continue to be investigated. 22 Uplifting, though, is evidence on the sustained protective effect of male circumcision witnessed, for example, in 42-month data from the Kisumu, Kenya Trial reported at the XVII International AIDS Conference in Mexico City. 23 No 10. At long last, new hope was infused into South Africa's fight against HIV/AIDS following the removal of that country's HIV-causes-AIDS denialist Minister of Health, Manto Tshabalala-Msimang. This occurred in the midst of what some analysts described as the worst political crisis since apartheid: the ousting of South African President Thabo Mbeki, who was promptly replaced by an interim President, Kgalema Motlanthe. Upon taking office, Motlanthe stressed he would advance his predecessor's policies, which apparently did not include keeping his beleaguered Minister of Health. Her replacement has been named as antiapartheid veteran Barbara Hogan, whom many AIDS activists believe will usher in a desperately needed new approach to combating HIV/ AIDS and other health challenges in South Africa. 24 I wish to acknowledge the invaluable contributions made by the following thought-leaders in compiling our list of milestones: David R. Bangsberg, MD, MPH (Harvard University); John G. Bartlett, MD (Johns Hopkins University); Kevin Frost (American Foundation for AIDS Research); Peter Mugyenyi, MD (Joint Clinical Research Centre, Kampala, Uganda); Jean B. Nachega, MD, PhD (Johns Hopkins University, and Stellenbosch University, Cape Town, South Africa); Frank J. Oldham Jr (National Association of People With AIDS); Celso Ramos-Filho, MD, MSc (Federal University of Rio de Janeiro, Brazil); Badara Samb, MD (World Health Organization); and Renslow Sherer, MD (Project HOPE). As important, I am grateful to the growing number of clinicians who throughout the year provide invaluable insights and conduct peer reviews of manuscripts submitted for publication in JIAPAC. Finally, my thanks to our contributors and our readers-without whom we would neither have a journal to publish nor a global audience to benefit from papers whose aim is to improve clinical practicum in the field of HIV medicine.
